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Background: The precise efficacy of nucleoside analogue reverse-transcriptase inhibitors (NRTIs) in preventing and
inhibiting virus replication remains unknown in RT-SHIV infected Chinese-origin rhesus macaques (Ch RM).
Findings: Ch RM were inoculated intravenously with 200 TCID50 RT-SHIV and treated by gavage with NRTIs (20 mg
AZT and 10 mg 3TC twice per day) for four consecutive weeks beginning at one hour, on day 217 or 297 post
inoculation, respectively. Treatment with AZT/3TC inhibited transiently RT-SHIV replication during chronic infection,
but did not significantly affect peripheral blood CD4+ T cells in macaques. Treatment with AZT/3TC at 1 hour post
infection prevented RT-SHIV infection in two out of four animals during the 120-day observation period.
Conclusions: Therefore, the Ch RM model with RT-SHIV infection can be used to evaluate the efficacy of new NRTIs.
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Animal models, such as non-human primate (NHP)
models, are very useful for the preclinical evaluation of
anti-viral drugs and microbicides [1-3]. Due to a low sensi-
tivity of simian immunodeficiency virus (SIV) to non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and
some nucleoside reverse transcriptase inhibitors (NRTIs),
especially for post-exposure prophylaxis (PEP), a number
of RT-SHIV strains have been constructed to evaluate the
activity of HIV-specific drugs and microbicides both
in vitro and in macaques [4-8]. RT-SHIV carry HIV-1 re-
verse transcriptase (RT) gene, which is the target of
NNRTIs and NRTIs, suitable for evaluating the efficacy of
HIV RT inhibitors in macaques [1,9]. Up to now, RT-
SHIV is commonly used to study the effect of highly active
antiretroviral therapy (HAART) and antiviral resistance in
India origin rhesus macaques (In RM) [1], pigtailed mon-
key [9,10], and Chinese-origin rhesus macaques (Ch RM)
[11]. An increasing body of evidence demonstrates that
Ch RM are useful in evaluating the pathogenesis, vac-
cine, and therapeutic strategies for HIV/AIDS infection* Correspondence: qinchuan@pumc.edu.cn; virolab@cnilas.org
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unless otherwise stated.[11]; however, Ch RM are different from In RM in viral
infection, immunological response, and host genetic
background [12,13]. It is important to evaluate the virus
and infectious character in Ch RM. For example, Pal
et al. characterized vaginal transmission of RT-SHIV in
Ch RM and showed that RT-SHIV isolates were sensi-
tive to RT inhibitors in vitro [11]. However, the precise
efficacy of RT inhibitors in preventing and inhibiting
virus replication remains unknown in RT-SHIV/TC in-
fected Ch RM model. In this study, we choose two rep-
resentative NRTIs, zidovudine (AZT) and lamivudine
(3TC), to study their effect on preventing and inhibiting
virus replication in Ch RM.
Twelve healthy Ch RMs at 3 years of age (weighing at 4
kg, equal number of males and females) were born and
housed in a specific pathogen free (SPF) facility at Institute
of Laboratory Animal Science (ILAS), Chinese Academy of
Medical Sciences. All naïve animals were negative for tests
of simian type D retroviruses (SRV), simian T cell leukemia
virus-1 (STLV), simian immunodeficiency virus (SIV),
monkey B virus (BV), and tubercle bacillus (TB). Animal
care was compliant with the Institute of Laboratory Animal
Science Guidelines for the Care and Use of Laboratory An-
imals (est. 2006), and the experimental protocol was ap-
proved by the Animal Research and Care Committee of
ILAS (Additional file 1: Supplementary Materials and
Methods). Ch RM were inoculated intravenously with 200td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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5 copies/mL) cell-free RT-SHIV, in which
the RT gene of SIVmac239 was replaced with that of HIV-
1 clone HXBc2 [5,14,15] (Additional file 1: Supplementary
Materials and Methods). This dose was similar to the
amount of virus in a contaminated needle (estimated 25 μl
of blood from a patient with high viral load) through which
individuals obtained a primary infection, and was lower
than other studies in In RM [1]. Those macaques were ran-
domized and provided with sterile water during the obser-
vation period as the controls [16], or treated by oral gavage
twice per day with both 20 mg AZT (Sigma, St. Louis,
USA) and 10 mg 3TC (Sigma, calculated, according to
body surface area, similar to that of human use) [17] begin-
ning at one hour after virus inoculation for four consecu-
tive weeks as the PEP group. These drug powders were
weighed and mixed prior to delivery. Four additional ma-
caques were treated by oral gavage with the same dose of
AZT and 3TC twice per day beginning on day 217 or 297
post virus inoculation, when the viremia had reached a
plateau, as the therapeutic group. Following inoculation
and treatment, the contents of plasma virus and the
numbers of peripheral CD4+ T cells were determined
longitudinally by quantitative RT-PCR (Additional file
1: Supplementary Materials and Methods) and flow cy-
tometry analysis [18] (Additional file 1: Supplementary
Materials and Methods), respectively.
As expected, plasma RT-SHIV-specific RNA was de-
tected in the control group of macaques and reached a
peak of 0.69 ~ 6.30 × 106 copies per ml at 1 or 3 weeks

















































Figure 1 The levels of plasma viral loads and peripheral blood CD4+
mean number of copies of viral RNA (red line) and peripheral blood CD4+
period. The areas of pockmarks show the time periods with AZT/3TC or wareport that RT-SHIV effectively infects Ch RM [11]. Eight
to 12 weeks after infection, RT-SHIV viremia reached a
plateau and maintained a high level of 1.0 to 3.5 × 104
copies per ml in the control group of macaques through-
out the observation period. Furthermore, treatment with a
combination of AZT with 3TC starting on day 297 or 217
post-infection significantly reduced the levels of plasma
viral loads in these macaques (G1102V, G1104V, G1112V
and G1114V), and the levels of viremia in those experi-
mental monkeys were lower than that of the detection
threshold (virus RNA load <100 copies/mL) at most time
points post drug treatment (Figure 2). These data indi-
cated that treatment with both AZT and 3TC inhibited
RT-SHIV replication in macaques. More importantly,
treatment with both AZT and 3TC one hour after in-
oculation dramatically prevented and inhibited RT-
SHIV replication in macaques. Evidentially, there was
no detectable viremia and viral RNA in three macaques
throughout the drug treatment period, and only mod-
erate levels of viremia were detected in another ma-
caque (G1105V) at the phase of drug treatment. One
(G1116V) out of three treated monkeys had viral re-
bound after the end of drug treatment. Similar patterns
of provirus DNA were detected in the PBMC of the
different groups of monkeys (data not shown). Inter-
estingly, the numbers of peripheral blood CD4+ T cells
at the end of the observation period were similar to
that at the baseline, except for one macaque (G1102V)
that received AZT/3TC on day 297 post inoculation




















































T cells in individual control macaques. Data are expressed as the
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ells
Figure 2 The levels of plasma viral loads and peripheral blood CD4+ T cells in individual macaques treated with AZT/3TC on day 297
or 217 post inoculation. Data are expressed as the mean number of copies of viral RNA (red line) and peripheral blood CD4+ T cells (blue line)
of individual macaques through the observation period. The areas of pockmarks show the time periods with AZT/3TC or water gavage.
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no obvious clinical symptoms in the infected animals,
including G1102V, and these animals remained healthy
during the experimental period. Therefore, treatment
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Figure 3 The levels of plasma viral loads and peripheral blood CD4+
post inoculation. Data are expressed as the mean number of copies of vir
individual macaques through the observation period. The areas of pockmainhibited RT-SHIV replication, but had little effect on
the numbers of peripheral blood CD4+ T cells in
macaques.
This study provided evidence to demonstrate that treat-
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SHIV strains, in which the RT was replaced with the RT
from an HIV-1 clone, have been constructed to evaluate
the efficacy and safety of HIV-specific NNRTIs and NRTIs
both in vitro and in macaques [1,5,6,19]. These stains of
viruses are not only highly sensitive to HIV-1 RT-specific
NNRTIs, but also to a variety of NRTIs and protease in-
hibitors, which inhibit virus replication [1,15]. Hence, RT-
SHIV is an appropriate virus for challenge to evaluate the
efficacy of anti-HIV NNRTIs and NRTIs. Although In RM
macaque is commonly used in biological studies as non-
human primate, the limited numbers of In RM macaques
available for research have hampered our studies to under-
stand the AIDS pandemic. In addition, studies of non-
human primate in a single model of animals may lead to
biased results and misleading findings [20]. The Ch RM
have a big population available for research and represent
a potential resource of animals for expanding the current
research efforts. In this study, we infected Ch RM with
200 TCID50 RT-SHIV and observed that treatment with
both AZT and 3TC one hour post inoculation prevented
RT-SHIV replication in two out of four macaques and
treatment with the same drugs at peak infection inhibited
virus replication in four macaques. These data indicated
that RT-SHIV was sensitive to NRTIs in Ch RM. Conceiv-
ably, treatment with these medicines may effectively pre-
vent HIV replication and AIDS development if a natural
infection occurs with a dose of HIV. Our data are consist-
ent with a previous report that prophylactic treatment
with a single substance post exposure reduces the prob-
ability of an infection [21]. Our results suggest that the
animal model infected with RT-SHIV can be used to
evaluate new NRTIs for the treatment and prevention of
AIDS.
In summary, our data indicate that AZT and 3TC treat-
ment post inoculation of RT-SHIV can prevent and inhibit
RT-SHIV replication in Ch RM. Therefore, the RT-SHIV/
Ch RM model may be valuable to evaluate NRTIs.Additional file
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